CD8A and neoplasm: ,4 Clinical trials have revealed that “hot” tumors (immune inflamed with high CD8+ T cell infiltration) respond to ICIs, whereas “cold” tumors (immune desert/exclusive with low CD8+ T cell infiltration) require co-treatment to improve the anti-tumor efficacy.3